Key Takeaways Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO.Dr. Edward Kaye ...

The administration’s bombing campaign against the Iran-backed group is running up against America's political and industrial ...

Ed Kaye, former CEO of Sarepta Therapeutics, is stepping down from his current role as chief executive of a Boston-area ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. Stoke on Tuesday said Ian Smith, a board member since September ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 64.71% and 483.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

A teacher's battle with skin cancer inspired her students to raise funds for a hospital charity. Pupils from Orme Academy in ...

BEDFORD, Mass. - Stoke Therapeutics, Inc. (NASDAQ: STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth ...

George Weaver joins BBC Radio Stoke's Lucas Yeomans to discuss the Potters' last-gasp defeat by Millwall at The Den.

Plans have been approved to knock down a "rundown" former Stoke-on-Trent school and youth centre plagued by "ongoing ...